Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

T2 Biosystems

Nasdaq:TTOO
Snowflake Description

Limited growth with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TTOO
Nasdaq
$65M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. The last earnings update was 12 days ago. More info.


Add to Portfolio Compare Print
  • T2 Biosystems has significant price volatility in the past 3 months.
TTOO Share Price and Events
7 Day Returns
69.6%
NasdaqGM:TTOO
6.3%
US Biotechs
12.6%
US Market
1 Year Returns
-75.4%
NasdaqGM:TTOO
1.6%
US Biotechs
-9.1%
US Market
TTOO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
T2 Biosystems (TTOO) 69.6% -27.4% -41.3% -75.4% -87.7% -96.2%
US Biotechs 6.3% -7.9% -7.9% 1.6% 7.7% -8.8%
US Market 12.6% -16.7% -19.6% -9.1% 8.2% 21.5%
1 Year Return vs Industry and Market
  • TTOO underperformed the Biotechs industry which returned 1.6% over the past year.
  • TTOO underperformed the Market in United States of America which returned -9.1% over the past year.
Price Volatility
TTOO
Industry
5yr Volatility vs Market

TTOO Value

 Is T2 Biosystems undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether T2 Biosystems is trading at an attractive price based on the cash flow it is expected to produce in the future. But as T2 Biosystems has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for T2 Biosystems. This is due to cash flow or dividend data being unavailable. The share price is $0.646.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for T2 Biosystems's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are T2 Biosystems's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:TTOO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.30
NasdaqGM:TTOO Share Price ** NasdaqGM (2020-03-27) in USD $0.65
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.87x
United States of America Market PE Ratio Median Figure of 2,935 Publicly-Listed Companies 13.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of T2 Biosystems.

NasdaqGM:TTOO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:TTOO Share Price ÷ EPS (both in USD)

= 0.65 ÷ -1.30

-0.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • T2 Biosystems is loss making, we can't compare its value to the US Biotechs industry average.
  • T2 Biosystems is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does T2 Biosystems's expected growth come at a high price?
Raw Data
NasdaqGM:TTOO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.5x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
9.1%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for T2 Biosystems, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on T2 Biosystems's assets?
Raw Data
NasdaqGM:TTOO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-0.67
NasdaqGM:TTOO Share Price * NasdaqGM (2020-03-27) in USD $0.65
United States of America Biotechs Industry PB Ratio Median Figure of 428 Publicly-Listed Biotechs Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,145 Publicly-Listed Companies 1.27x
NasdaqGM:TTOO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:TTOO Share Price ÷ Book Value per Share (both in USD)

= 0.65 ÷ -0.67

-0.96x

* Primary Listing of T2 Biosystems.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • T2 Biosystems has negative assets, we can't compare the value of its assets to the US Biotechs industry average.

Next steps:

  1. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through T2 Biosystems's regulatory filings and announcements.
  2. Show me more potentially undervalued companies in the Biotechs industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess T2 Biosystems's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. T2 Biosystems has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

TTOO Future Performance

 How is T2 Biosystems expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
9.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is T2 Biosystems expected to grow at an attractive rate?
  • Unable to compare T2 Biosystems's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare T2 Biosystems's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • T2 Biosystems's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:TTOO Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:TTOO Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 9.1%
NasdaqGM:TTOO Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 41.6%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:TTOO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:TTOO Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 35 -53 1
2021-12-31 24 -45 3
2020-12-31 14 -49 3
2020-03-28
NasdaqGM:TTOO Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 8 -45 -59
2019-09-30 7 -45 -60
2019-06-30 8 -41 -57
2019-03-31 10 -41 -53
2018-12-31 11 -40 -51
2018-09-30 10 -42 -54
2018-06-30 9 -43 -58
2018-03-31 6 -47 -61
2017-12-31 5 -48 -62
2017-09-30 4 -47 -59
2017-06-30 4 -47 -57
2017-03-31 4 -47 -56

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • T2 Biosystems is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • T2 Biosystems's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:TTOO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from T2 Biosystems Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:TTOO Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 -1.05 -1.05 -1.05 1.00
2021-12-31 -0.76 -0.36 -1.26 3.00
2020-12-31 -0.87 -0.42 -1.19 3.00
2020-03-28
NasdaqGM:TTOO Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.30
2019-09-30 -1.35
2019-06-30 -1.28
2019-03-31 -1.25
2018-12-31 -1.26
2018-09-30 -1.41
2018-06-30 -1.62
2018-03-31 -1.81
2017-12-31 -1.94
2017-09-30 -1.91
2017-06-30 -1.97
2017-03-31 -2.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if T2 Biosystems will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess T2 Biosystems's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
T2 Biosystems has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

TTOO Past Performance

  How has T2 Biosystems performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare T2 Biosystems's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • T2 Biosystems does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare T2 Biosystems's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare T2 Biosystems's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
T2 Biosystems's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from T2 Biosystems Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:TTOO Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 8.34 -59.01 27.30
2019-09-30 7.06 -60.11 26.22
2019-06-30 7.85 -56.71 26.11
2019-03-31 9.97 -53.39 27.00
2018-12-31 10.50 -51.15 25.70
2018-09-30 10.37 -54.20 24.80
2018-06-30 9.01 -57.51 24.49
2018-03-31 6.04 -60.64 22.64
2017-12-31 4.67 -62.43 22.76
2017-09-30 3.91 -58.78 22.99
2017-06-30 3.89 -57.49 23.36
2017-03-31 3.93 -56.08 23.75
2016-12-31 4.08 -54.80 24.08
2016-09-30 4.18 -52.29 23.29
2016-06-30 4.15 -51.15 22.54
2016-03-31 3.72 -48.10 20.83
2015-12-31 2.81 -45.29 19.09
2015-09-30 1.92 -42.33 17.83
2015-06-30 0.87 -39.54 15.64
2015-03-31 0.31 -37.75 13.64
2014-12-31 0.12 -35.96 11.02
2014-09-30 0.06 -35.17 8.68
2014-06-30 0.15 -32.87 6.97
2014-03-31 0.27 -30.59 5.83
2013-12-31 0.27 -27.52 5.02

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if T2 Biosystems has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if T2 Biosystems has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if T2 Biosystems improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess T2 Biosystems's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
T2 Biosystems has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

TTOO Health

 How is T2 Biosystems's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up T2 Biosystems's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • T2 Biosystems's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • T2 Biosystems's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of T2 Biosystems's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • T2 Biosystems has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from T2 Biosystems Company Filings, last reported 2 months ago.

NasdaqGM:TTOO Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -34.01 45.33 11.03
2019-09-30 -25.91 44.86 16.21
2019-06-30 -15.62 44.93 28.42
2019-03-31 -1.58 44.07 37.40
2018-12-31 11.39 44.52 50.81
2018-09-30 23.76 42.27 60.23
2018-06-30 31.98 43.99 70.71
2018-03-31 -10.09 44.01 29.73
2017-12-31 1.34 43.94 41.80
2017-09-30 18.13 41.51 52.90
2017-06-30 12.33 41.27 46.13
2017-03-31 26.03 41.07 58.82
2016-12-31 39.34 40.77 73.49
2016-09-30 50.58 32.74 75.11
2016-06-30 22.66 34.80 50.22
2016-03-31 35.09 30.52 59.52
2015-12-31 46.94 30.57 73.66
2015-09-30 23.81 20.76 40.12
2015-06-30 34.05 20.83 53.29
2015-03-31 43.48 20.89 65.30
2014-12-31 53.00 20.96 73.85
2014-09-30 61.43 11.02 75.59
2014-06-30 10.87 4.18 15.88
2014-03-31 17.71 11.28 30.32
2013-12-31 24.50 5.06 30.20
  • T2 Biosystems has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if T2 Biosystems's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • T2 Biosystems has less than a year of cash runway based on current free cash flow.
  • T2 Biosystems has less than a year of cash runway if free cash flow continues to grow at historical rates of 8.6% each year.
X
Financial health checks
We assess T2 Biosystems's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. T2 Biosystems has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

TTOO Dividends

 What is T2 Biosystems's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from T2 Biosystems dividends.
If you bought $2,000 of T2 Biosystems shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate T2 Biosystems's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate T2 Biosystems's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:TTOO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:TTOO Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as T2 Biosystems has not reported any payouts.
  • Unable to verify if T2 Biosystems's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of T2 Biosystems's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as T2 Biosystems has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess T2 Biosystems's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can T2 Biosystems afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. T2 Biosystems has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

TTOO Management

 What is the CEO of T2 Biosystems's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Sperzel
AGE 55
TENURE AS CEO 0.2 years
CEO Bio

Mr. John J. Sperzel, III, B.Sc., serves as President, Chief Executive Officer and Director of T2 Biosystems, Inc. since January 8, 2020. Mr. Sperzel served as the Chief Executive Officer and President of Chembio Diagnostics, Inc. since March 13, 2014 until January 2020. Prior to Chembio, Mr. Sperzel served as President and CEO of ITC Medical. Mr. Sperzel served as the Chief Executive Officer of International Technidyne Corporation since September 2011 until December 2013. He serves as an Advisor to the board of the Diagnostic Marketing Association. Mr. Sperzel served as President of Axis-Shield Inc. at Axis-Shield PLC since August 11, 2004. He served as Vice President of World Wide Marketing and Business Development for Near Patient Testing at Bayer Diagnostics. He has worked in the Diagnostics Industry for years at Roche (Boehringer Mannheim), Instrumentation Laboratory and Bayer HealthCare. He joined Axis-Shield in 2004 from Bayer Diagnostics, where he served as Vice President of Worldwide Marketing and Business Development for Near Patient Testing. He was the president of the board of Diagnostic Marketing Association since 2007. He served as a Director of International Technidyne Corporation since September 2011 until December 2013. He has been a Director of diaDexus Inc since June 2015. He served as a Director of Chembio Diagnostics, Inc. since March 2014 until January 2020. Mr. Sperzel holds a B.S. in Business Administration/Management Degree from Plymouth State College (Plymouth NH).

CEO Compensation
  • Insufficient data for John to compare compensation growth.
  • Insufficient data for John to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the T2 Biosystems management team in years:

4.2
Average Tenure
55
Average Age
  • The tenure for the T2 Biosystems management team is about average.
Management Team

Michael Cima

TITLE
Co-Founder & Director
COMPENSATION
$147K
AGE
59

John Sprague

TITLE
CFO & Senior VP
COMPENSATION
$1M
AGE
60
TENURE
2.2 yrs

Tom Lowery

TITLE
Chief Scientific Officer
COMPENSATION
$1M
AGE
40
TENURE
6.5 yrs

John Sperzel

TITLE
President
AGE
55
TENURE
0.2 yrs

Tyler Jacks

TITLE
Co-Founder
AGE
58
TENURE
14.2 yrs

Lee Josephson

TITLE
Co-Founder & Member of Scientific Advisory Board
TENURE
14.2 yrs

Alec Barclay

TITLE
Senior Vice President of Operations
AGE
38
TENURE
2 yrs

Michael Gibbs

TITLE
VP & General Counsel
AGE
48
TENURE
4.2 yrs

Kelley Morgan

TITLE
Vice President of Human Resources
TENURE
6 yrs

Tony Pare

TITLE
Chief Commercial Officer
TENURE
0.2 yrs
Board of Directors Tenure

Average tenure and age of the T2 Biosystems board of directors in years:

7.3
Average Tenure
64
Average Age
  • The tenure for the T2 Biosystems board of directors is about average.
Board of Directors

John McDonough

TITLE
Non-Executive Chairman
COMPENSATION
$4M
AGE
59
TENURE
0.7 yrs

Michael Cima

TITLE
Co-Founder & Director
COMPENSATION
$147K
AGE
59
TENURE
14.2 yrs

John Sperzel

TITLE
President
AGE
55
TENURE
0.2 yrs

Lee Josephson

TITLE
Co-Founder & Member of Scientific Advisory Board

Stan Lapidus

TITLE
Independent Director
COMPENSATION
$176K
AGE
70
TENURE
11.6 yrs

David Elsbree

TITLE
Independent Director
COMPENSATION
$153K
AGE
71
TENURE
5.7 yrs

T. Boles

TITLE
Member of Scientific Advisory Board

Harold Kisner

TITLE
Member of Scientific Advisory Board

Alex Klibanov

TITLE
Member of Scientific Advisory Board
AGE
69

Peter Pappas

TITLE
Member of Clinical Advisory Board
TENURE
8.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess T2 Biosystems's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. T2 Biosystems has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

TTOO News

Simply Wall St News

Is There An Opportunity With T2 Biosystems, Inc.'s (NASDAQ:TTOO) 24% Undervaluation?

Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to their present value. … We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. … Generally we assume that a dollar today is more valuable than a dollar in the future, so we discount the value of these future cash flows to their estimated value in today's dollars: 10-year free cash flow (FCF) estimate 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 Levered FCF ($, Millions) $-38.8m $-15.2m $6.4m $9.6m $13.1m $16.5m $19.7m $22.5m $24.9m $26.9m Growth Rate Estimate Source Analyst x1 Analyst x1 Analyst x1 Est @ 50.39% Est @ 36.09% Est @ 26.08% Est @ 19.08% Est @ 14.17% Est @ 10.74% Est @ 8.34% Present Value ($, Millions) Discounted @ 12.99% $-34.3 $-11.9 $4.4 $5.9 $7.1 $7.9 $8.4 $8.5 $8.3 $7.9 ("Est" = FCF growth rate estimated by Simply Wall St) Present Value of 10-year Cash Flow (PVCF)= $12.2m We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period.

Simply Wall St -

If You Had Bought T2 Biosystems (NASDAQ:TTOO) Stock Three Years Ago, You'd Be Sitting On A 78% Loss, Today

Check out our latest analysis for T2 Biosystems T2 Biosystems isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … When a company doesn't make profits, we'd generally expect to see good revenue growth. … Ultimately, revenue growth doesn't amount to much if the business can't scale well.

Simply Wall St -

Is T2 Biosystems, Inc. (NASDAQ:TTOO) A Volatile Stock?

Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market. … If this beta value holds true in the future, T2 Biosystems shares are likely to rise more than the market when the market is going up, but fall faster when the market is going down. … What this means for you: Since T2 Biosystems has a reasonably high beta, it's worth considering why it is so heavily influenced by broader market sentiment.

Simply Wall St -

Should You Worry About T2 Biosystems, Inc.'s (NASDAQ:TTOO) CEO Pay?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does John McDonough's Compensation Compare With Similar Sized Companies. … is worth US$127m, and total annual CEO compensation is US$1.3m.

Simply Wall St -

When Will T2 Biosystems, Inc. (NASDAQ:TTOO) Turn A Profit?

As path to profitability is the topic on TTOO’s investors mind, I’ve decided to gauge market sentiment. … I’ve put together a brief outline of industry analyst expectations for TTOO, its year of breakeven and its implied growth rate … Check out our latest analysis for T2 Biosystems

Simply Wall St -

Imagine Owning T2 Biosystems While The Price Tanked 50%

In that time, the share price dropped 50%. … T2 Biosystems isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … The share price has moved in quite the opposite direction, down 21% over that time, a bad result.

Simply Wall St -

Could The T2 Biosystems, Inc. (NASDAQ:TTOO) Ownership Structure Tell Us Something Useful?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … We also tend to see lower insider ownership in companies that were previously publicly owned. … institutions own shares in the company.

Simply Wall St -

Why T2 Biosystems Inc's (NASDAQ:TTOO) CEO Pay Matters To You

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does John McDonough's Compensation Compare With Similar Sized Companies. … Our data indicates that T2 Biosystems Inc is worth US$196m, and total annual CEO compensation is US$1.3m.

Simply Wall St -

Does The T2 Biosystems Inc (NASDAQ:TTOO) Share Price Fall With The Market?

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

Want To Invest In T2 Biosystems Inc (NASDAQ:TTOO)? Here's How It Performed Lately

After reading T2 Biosystems Inc's (NASDAQ:TTOO) latest earnings update (30 June 2018), I found it beneficial to look back at how the company has performed in the past and compare this against the most recent numbers. … Did TTOO's recent performance beat its trend and industry. … TTOO is loss-making, with the most recent trailing twelve-month earnings of -US$57.50m (from 30 June 2018), which compared to last year has become

Simply Wall St -

TTOO Company Info

Description

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it is developing Candida Auris, a multi-drug resistant pathogen; T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; and T2Lyme for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC to develop detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate, as well as for testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Details
Name: T2 Biosystems, Inc.
TTOO
Exchange: NasdaqGM
Founded: 2006
$65,086,350
100,752,864
Website: http://www.t2biosystems.com
Address: T2 Biosystems, Inc.
101 Hartwell Avenue,
Lexington,
Massachusetts, 02421,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM TTOO Common Stock Nasdaq Global Market US USD 07. Aug 2014
DB 3T2 Common Stock Deutsche Boerse AG DE EUR 07. Aug 2014
Number of employees
Current staff
Staff numbers
151
T2 Biosystems employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 02:53
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/25
Last earnings filing: 2020/03/16
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.